Pfizer Inc. (NYSE:PFE) Shares Purchased by TCW Group Inc.

TCW Group Inc. boosted its stake in Pfizer Inc. (NYSE:PFE) by 4.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 79,396 shares of the biopharmaceutical company’s stock after purchasing an additional 3,316 shares during the period. TCW Group Inc.’s holdings in Pfizer were worth $2,222,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Olistico Wealth LLC acquired a new stake in Pfizer in the 2nd quarter valued at $25,000. Creekmur Asset Management LLC acquired a new stake in shares of Pfizer during the fourth quarter valued at about $32,000. Trivant Custom Portfolio Group LLC grew its stake in shares of Pfizer by 100.0% during the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 600 shares in the last quarter. Tennessee Valley Asset Management Partners acquired a new stake in shares of Pfizer during the fourth quarter valued at about $36,000. Finally, DiNuzzo Private Wealth Inc. acquired a new stake in shares of Pfizer during the fourth quarter valued at about $37,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Down 1.4 %

Pfizer stock opened at $28.30 on Monday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. Pfizer Inc. has a one year low of $25.20 and a one year high of $37.19. The company has a 50-day simple moving average of $28.75 and a 200-day simple moving average of $27.91. The firm has a market capitalization of $160.36 billion, a P/E ratio of -471.67, a P/E/G ratio of 1.00 and a beta of 0.69.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.14. The company had revenue of $13.28 billion during the quarter, compared to analysts’ expectations of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The company’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.67 earnings per share. As a group, equities analysts expect that Pfizer Inc. will post 2.68 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 26th will be paid a dividend of $0.42 per share. The ex-dividend date is Friday, July 26th. This represents a $1.68 annualized dividend and a yield of 5.94%. Pfizer’s dividend payout ratio is currently -2,800.00%.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on PFE. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Morgan Stanley upped their target price on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research note on Thursday, May 2nd. Wells Fargo & Company boosted their price objective on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and increased their target price for the stock from $28.00 to $34.00 in a report on Wednesday, August 7th. Finally, Barclays upped their price target on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. Eight equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $34.54.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.